The BsAbs, currently approved and under investigation for MM are directed against BCMA (teclistamab and elranatamab), GPRC5D (talquetamab), the homolog of the Fc 5 receptor (FcRH5) and CD38 on PCs. This evidence concerns the gene GPRC5D and Miyoshi myopathy.